论文部分内容阅读
用肝细胞癌手术切除标本,制备细胞悬液,免疫BALB/c小鼠,通过杂交瘤技术,获得一组高亲和性肝癌单抗HAb18,F11,E5,A10,四株抗体经免疫组化染色,均显示对肝细胞癌有较好的选择性.用碘标记F11,E5,A10,HAb18IgG及其F(a b′)_2片段抗体,对荷肝癌裸鼠进行放射免疫显像,显示出较好的定位作用.其瘤/肝比值分别为6.88,5.14;5.67,5.15,14.47均比有关文献(Dunk AA,1987)报道的定位效果好.用~(131)I-HAb18IgG及其片段抗体进行荷肝癌裸鼠的放免导向治疗,其显效者为5/12;部分缓解者为6/12.HAb18碘标记物经质控,符合“人用鼠源性单抗的制备及质量控制要点”并进行肝癌病人的体内显像,阳性率达86.5%(45/52),其中最小定位的肿瘤直径仅0.5cm;用于体内导向治疗,部分缓解率达69.6%(16/23).以上研究为肿瘤的综合治疗开辟了新路径.
The hepatoma was surgically resected and the cell suspension was prepared. BALB/c mice were immunized. A group of high-affinity monoclonal antibodies HAb18, F11, E5, and A10 were obtained by immunohistochemistry. Staining showed good selectivity for hepatocellular carcinoma. Radioimmunoimaging was performed on nude mice bearing hepatocellular carcinoma with iodine-labeled F11, E5, A10, HAb18 IgG and their F(ab’)_2 fragment antibodies. Good localization effect. The tumor/liver ratios were 6.88, 5.14; 5.67, 5.15, and 14.47, respectively, which were better than those reported in the related literature (Dunk AA, 1987). These were performed using ~(131)I-HAb18 IgG and its fragment antibodies. Liver cancer hepatocellular carcinoma nude mice radioimmunotherapy-oriented treatment, the effective rate was 5/12; partial remission was 6/12. HAb18 iodine label quality control, in line with “human preparation of mouse monoclonal antibody and quality control points” and In vivo imaging of patients with liver cancer, the positive rate of 86.5% (45/52), of which the smallest localized tumor diameter of only 0.5cm; for in vivo-oriented treatment, partial remission rate of 69.6% (16/23). The above study was Comprehensive treatment of tumors opens up new paths.